Human papillomavirus vaccines: current status and future prospects (Q37762242)

22 August 2017

1 reference

title

Human papillomavirus vaccines: current status and future prospects (English)

1 reference

22 August 2017

1 reference

Suzanne Marie Garland

series ordinal

1

object named as

Suzanne M Garland

1 reference

22 August 2017

Jennifer S Smith

2

1 reference

22 August 2017

publication date

1 June 2010

1 reference

22 August 2017

1 reference

22 August 2017

volume

70

1 reference

22 August 2017

issue

9

1 reference

22 August 2017

page(s)

1079-1098

1 reference

Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention

22 August 2017

cites work

1 reference

https://api.crossref.org/works/10.2165/10898580-000000000-00000

The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/10898580-000000000-00000

Human papillomavirus type-distribution in vulvar and vaginal cancers and their associated precursors

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/10898580-000000000-00000

The causal relation between human papillomavirus and cervical cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/10898580-000000000-00000

Herpes simplex virus-2 as a human papillomavirus cofactor in the etiology of invasive cervical cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/10898580-000000000-00000

Safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for cervical cancer prevention: a pooled analysis of 11 clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/10898580-000000000-00000

Anaphylaxis following quadrivalent human papillomavirus vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/10898580-000000000-00000

Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials

21 January 2018

1 reference

12 December 2020

Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women

1 reference

12 December 2020

Noninferiority of antibody response to human papillomavirus type 16 in subjects vaccinated with monovalent and quadrivalent L1 virus-like particle vaccines

1 reference

12 December 2020

Descriptive Evidence That Risk Profiles for Cervical Intraepithelial Neoplasia 1, 2, and 3 Are Unique

1 reference

12 December 2020

Human papillomavirus type distribution in anal cancer and anal intraepithelial lesions

1 reference

12 December 2020

Immune responses to human papillomavirus

1 reference

12 December 2020

Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women

1 reference

12 December 2020

Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study

1 reference

12 December 2020

Lung cancer and cigarette smoking in Europe: an update of risk estimates and an assessment of inter-country heterogeneity

1 reference

12 December 2020

Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18

1 reference

12 December 2020

Persistent human papillomavirus infection and cervical neoplasia: a systematic review and meta-analysis

1 reference

12 December 2020

Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases

1 reference

12 December 2020

Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial

1 reference

12 December 2020

Do human papillomavirus infections cause oral cancer?

1 reference

12 December 2020

Safety and immunogenicity of co-administered quadrivalent human papillomavirus (HPV)-6/11/16/18 L1 virus-like particle (VLP) and hepatitis B (HBV) vaccines

1 reference

12 December 2020

Population-based enrolment of adolescents in a long-term follow-up trial of human papillomavirus vaccine efficacy

1 reference

12 December 2020

Age-specific prevalence of infection with human papillomavirus in females: a global review

1 reference

12 December 2020

High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up

1 reference

12 December 2020

Results of the first WHO international collaborative study on the standardization of the detection of antibodies to human papillomaviruses.

1 reference

12 December 2020

Rapid decline in presentations of genital warts after the implementation of a national quadrivalent human papillomavirus vaccination programme for young women.

1 reference

12 December 2020

Interim estimates of human papillomavirus vaccination coverage in the school-based program in Australia.

1 reference

12 December 2020

Age considerations when vaccinating against HPV.

1 reference

12 December 2020

Case-control study of human papillomavirus and oropharyngeal cancer

1 reference

12 December 2020

The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years

1 reference

12 December 2020

Early experience with human papillomavirus vaccine introduction in the United States, Canada and Australia

1 reference

12 December 2020

Human papillomavirus vaccine recommendations and agreement with mandated human papillomavirus vaccination for 11-to-12-year-old girls: a statewide survey of Texas physicians

1 reference

12 December 2020

Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial

1 reference

12 December 2020

Expression of human papillomavirus type 11 L1 protein in insect cells: in vivo and in vitro assembly of viruslike particles

1 reference

12 December 2020

Chapter 3: Cofactors in human papillomavirus carcinogenesis--role of parity, oral contraceptives, and tobacco smoking.

1 reference

12 December 2020

Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial

1 reference

12 December 2020

Singaporean men's knowledge of cervical cancer and human papillomavirus (HPV) and their attitudes towards HPV vaccination

1 reference

12 December 2020

Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection

1 reference

12 December 2020

Hypersensitivity reactions to human papillomavirus vaccine in Australian schoolgirls: retrospective cohort study

1 reference

12 December 2020

Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine

1 reference

12 December 2020

High incidence of cervical human papillomavirus infection in women during their first sexual relationship

1 reference

12 December 2020

Enrolment of 22,000 adolescent women to cancer registry follow-up for long-term human papillomavirus vaccine efficacy: guarding against guessing

1 reference

12 December 2020

Human papillomavirus and cervical cancer in Australasia and Oceania: risk-factors, epidemiology and prevention

1 reference

12 December 2020

Antibody levels and protection after hepatitis B vaccine: results of a 22-year follow-up study and response to a booster dose

1 reference

12 December 2020

Human papillomavirus and cervical cancer

1 reference

12 December 2020

Natural History of Cervicovaginal Papillomavirus Infection in Young Women

1 reference

12 December 2020

Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update.

1 reference

12 December 2020

A review of human carcinogens--Part B: biological agents

1 reference

12 December 2020

A study of women's knowledge regarding human papillomavirus infection, cervical cancer and human papillomavirus vaccines

1 reference

12 December 2020

Introduction of human papillomavirus vaccines into developing countries - international strategies for funding and procurement

1 reference

12 December 2020

Singaporean women's knowledge of human papillomavirus (HPV) and attitudes toward HPV vaccination

1 reference

12 December 2020

HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine

1 reference

12 December 2020

Chlamydia trachomatis and invasive cervical cancer: a pooled analysis of the IARC multicentric case-control study

1 reference

12 December 2020

Systematic review of human papillomavirus prevalence in invasive penile cancer

1 reference

12 December 2020

Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine

1 reference

12 December 2020

Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine.

1 reference

12 December 2020

Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18.

1 reference

12 December 2020

National, state, and local area vaccination coverage among adolescents aged 13-17 years--United States, 2008.

1 reference

12 December 2020

Human papillomavirus genotype distribution in low-grade cervical lesions: comparison by geographic region and with cervical cancer

1 reference

12 December 2020

HPV vaccine continues to be safe and effective, and its benefits continue to outweigh its risks.

1 reference

12 December 2020

The relationship of community biopsy-diagnosed cervical intraepithelial neoplasia grade 2 to the quality control pathology-reviewed diagnoses: an ALTS report

1 reference

12 December 2020

Efficacy and other milestones for human papillomavirus vaccine introduction

1 reference

12 December 2020

Juvenile laryngeal papillomatosis in a pediatric population: a clinicopathologic study

1 reference

12 December 2020

Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant

1 reference

12 December 2020

Human papillomavirus infections among couples in new sexual relationships

1 reference

12 December 2020

Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection

1 reference

12 December 2020

Lifelong protection against hepatitis B: the role of vaccine immunogenicity in immune memory

1 reference

12 December 2020

Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women

1 reference

12 December 2020

Knowledge and awareness of human papillomavirus (HPV): attitudes towards HPV vaccination among a representative sample of women in Victoria, Australia

1 reference

12 December 2020

Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis

1 reference

12 December 2020

Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years

1 reference

12 December 2020

Longer term efficacy of a prophylactic monovalent human papillomavirus type 16 vaccine

1 reference

12 December 2020

Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions

1 reference

12 December 2020

Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial

1 reference

12 December 2020

Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials

1 reference

12 December 2020

Self-assembly of human papillomavirus type 1 capsids by expression of the L1 protein alone or by coexpression of the L1 and L2 capsid proteins

1 reference

12 December 2020

Availability of human papillomavirus vaccine at medical practices in an area with elevated rates of cervical cancer

1 reference

12 December 2020

10.2165/10898580-000000000-00000

Identifiers

DOI

1 reference

Dimensions Publication ID

22 August 2017

1001446320

0 references

1 reference